WeLeader Biomedical Co., Ltd. (TPEX:7713)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
70.80
-0.50 (-0.70%)
Jan 22, 2026, 11:20 AM CST
-8.05%
Market Cap3.24B
Revenue (ttm)1.06B
Net Income (ttm)191.02M
Shares Out45.48M
EPS (ttm)4.33
PE Ratio16.47
Forward PEn/a
Dividend3.37 (4.72%)
Ex-Dividend DateJun 3, 2025
Volume1,010
Average Volume11,868
Open70.30
Previous Close71.30
Day's Range70.30 - 70.80
52-Week Range54.20 - 83.00
Beta0.16
RSI42.10
Earnings DateMar 13, 2026

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr... [Read more]

Sector Healthcare
Founded 1992
Employees 199
Stock Exchange Taipei Exchange
Ticker Symbol 7713
Full Company Profile

Financial Performance

In 2024, WeLeader Biomedical's revenue was 991.13 million, an increase of 5.36% compared to the previous year's 940.70 million. Earnings were 170.21 million, an increase of 11.77%.

Financial Statements